Literature DB >> 3041283

Deactivation of macrophages by transforming growth factor-beta.

S Tsunawaki1, M Sporn, A Ding, C Nathan.   

Abstract

Macrophage activation--enhanced capacity to kill, in a cell that otherwise mostly scavenges--is essential for host survival from infection and contributes to containment of tumours. Both microbes and tumour cells, therefore, may be under pressure to inhibit or reverse the activation of macrophages. This reasoning led to the demonstration of macrophage deactivating factors from both microbes and tumour cells. In some circumstances the host itself probably requires the ability to deactivate macrophages. Macrophages are essential to the healing of wounds and repair of tissues damaged by inflammation. Yet the cytotoxic products of the activated macrophages can damage endothelium, fibroblasts, smooth muscle and parenchymal cells (reviewed in ref. 6). Thus, after an inflammatory site has been sterilized, the impact of macrophage activation on the host might shift from benefit to detriment. These concepts led us to search for macrophage deactivating effects among polypeptide growth factors that regulate angiogenesis, fibrogenesis and other aspects of tissue repair. Among 11 such factors, two proteins that are 71% similar proved to be potent macrophage deactivators: these are transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 2.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3041283     DOI: 10.1038/334260a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  208 in total

1.  Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform.

Authors:  J George; S S Wang; A M Sevcsik; M Sanicola; R L Cate; V E Koteliansky; D M Bissell
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  Latency-associated peptide of transforming growth factor beta enhances mycobacteriocidal immunity in the lung during Mycobacterium bovis BCG infection in C57BL/6 mice.

Authors:  K A Wilkinson; T D Martin; S M Reba; H Aung; R W Redline; W H Boom; Z Toossi; S A Fulton
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

3.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 4.  TGF-beta: problems and prospects.

Authors:  M B Sporn; A B Roberts
Journal:  Cell Regul       Date:  1990-11

Review 5.  Lung cancer vaccines.

Authors:  Ronan J Kelly; Giuseppe Giaccone
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

6.  Suppression of the reactive oxygen intermediates production of human macrophages by colorectal adenocarcinoma cell lines.

Authors:  A Siegert; C Denkert; A Leclere; S Hauptmann
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

7.  Multi-compartmental nanoparticles-in-emulsion formulation for macrophage-specific anti-inflammatory gene delivery.

Authors:  Husain Attarwala; Mansoor Amiji
Journal:  Pharm Res       Date:  2012-01-27       Impact factor: 4.200

Review 8.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

9.  Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis.

Authors:  A Barral; M Barral-Netto; E C Yong; C E Brownell; D R Twardzik; S G Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

10.  Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor.

Authors:  F M Kong; M S Anscher; T Murase; B D Abbott; J D Iglehart; R L Jirtle
Journal:  Ann Surg       Date:  1995-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.